Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Diabetes is accompanied by several complications. Higher prevalence of cancers, cardiovascular diseases, chronic kidney disease (CKD), obesity, osteoporosis, and neurodegenerative diseases has been reported among patients with diabetes. Metformin is the oldest oral antidiabetic drug and can improve coexisting complications of diabetes. Clinical trials and observational studies uncovered that metformin can remarkably prevent or alleviate cardiovascular diseases, obesity, polycystic ovarian syndrome (PCOS), osteoporosis, cancer, periodontitis, neuronal damage and neurodegenerative diseases, inflammation, inflammatory bowel disease (IBD), tuberculosis, and COVID-19. In addition, metformin has been proposed as an antiaging agent. Numerous mechanisms were shown to be involved in the protective effects of metformin. Metformin activates the LKB1/AMPK pathway to interact with several intracellular signaling pathways and molecular mechanisms. The drug modifies the biologic function of NF-κB, PI3K/AKT/mTOR, SIRT1/PGC-1α, NLRP3, ERK, P38 MAPK, Wnt/β-catenin, Nrf2, JNK, and other major molecules in the intracellular signaling network. It also regulates the expression of noncoding RNAs. Thereby, metformin can regulate metabolism, growth, proliferation, inflammation, tumorigenesis, and senescence. Additionally, metformin modulates immune response, autophagy, mitophagy, endoplasmic reticulum (ER) stress, and apoptosis and exerts epigenetic effects. Furthermore, metformin protects against oxidative stress and genomic instability, preserves telomere length, and prevents stem cell exhaustion. In this review, the protective effects of metformin on each disease will be discussed using the results of recent meta-analyses, clinical trials, and observational studies. Thereafter, it will be meticulously explained how metformin reprograms intracellular signaling pathways and alters molecular and cellular interactions to modify the clinical presentations of several diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging
Kujoth, G. C., Hiona, A., Pugh, T. D., Someya, S., Panzer, K., Wohlgemuth, S. E., Hofer, T., Seo, A. Y., Sullivan, R., Jobling, W. A., et al. (2005) · Science · doi:10.1126/science.1112125 · Cited by 2,165
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
Research works printed but not linked: 313
- 10.2991/jegh.k.191028.001 · DOI · Paper page
- 10.4103/2230-8210.141388 · DOI
- 10.1016/j.diabet.2019.11.004 · DOI
- 10.1002/hep.31142 · DOI · Paper page
- 10.2337/diaclin.26.2.77 · DOI · Paper page
- 10.1007/s11892-013-0425-5 · DOI · Paper page
- 10.1001/jamanetworkopen.2019.2696 · DOI · Paper page
- 10.1681/ASN.2019101119 · DOI · Paper page
- Crowley, M. J.; Diamantidis, C. J.; McDuffie, J. R.; Cameron, B.; Stanifer, J.; Mock, C. K.; Kosinski, A.; Wang, X.; Tang, S.; Williams, J. W., Jr. Metformin use in patients with historical contraindications or precautions. Department of Veterans Affairs, Washington, DC, 2017; https://www.ncbi.nlm.nih.gov/books/NBK409374/.
- 10.1016/j.dsx.2020.11.006 · DOI
- 10.3389/fendo.2020.559446 · DOI · Paper page
- 10.1158/1940-6207.CAPR-10-0157 · DOI · Paper page
- 10.1007/s13311-020-00878-7 · DOI
- 10.1016/j.febslet.2011.03.010 · DOI · Paper page
- 10.1186/s12933-019-0931-0 · DOI
- 10.1016/j.lfs.2020.117854 · DOI
- 10.22074/cellj.2020.6286 · DOI
- 10.1186/s13054-019-2346-4 · DOI
- 10.1038/ni.3772 · DOI · Paper page
- 10.3892/etm.2017.4475 · DOI
- 10.2174/1573397114666180717145745 · DOI
- 10.1186/s13046-018-0731-5 · DOI · Paper page
- 10.4049/jimmunol.1403088 · DOI · Paper page
- 10.1371/journal.pone.0117081 · DOI
- 10.1007/s00535-013-0891-1 · DOI
- 10.4049/jimmunol.1201767 · DOI
- 10.1111/jcmm.16269 · DOI
- Duan W., 2019, Am. J. Transl. Res., 11, 2393
- 10.4049/jimmunol.1901213 · DOI · Paper page
- 10.1016/j.biopha.2019.109458 · DOI
- 10.1016/j.mce.2017.09.025 · DOI · Paper page
- 10.7150/ijbs.29680 · DOI · Paper page
- Qing L., 2019, Am. J. Transl. Res., 11, 655
- 10.1210/clinem/dgaa951 · DOI
- 10.1007/s12016-013-8402-y · DOI · Paper page
- 10.1016/j.lfs.2018.02.017 · DOI
- 10.1186/s12933-017-0579-6 · DOI
- 10.1007/s00592-018-1129-8 · DOI · Paper page
- 10.1007/s00228-019-02786-y · DOI
- 10.3904/kjim.2017.249 · DOI
- 10.1093/infdis/jiz064 · DOI
- 10.7326/M16-1901 · DOI · Paper page
- 10.1161/CIRCHEARTFAILURE.112.000162 · DOI · Paper page
- 10.1016/j.diabres.2020.108001 · DOI
- 10.2337/dc19-0936 · DOI
- 10.1186/s12933-017-0509-7 · DOI
- 10.1155/2019/9484717 · DOI
- 10.1111/j.1440-1681.2010.05461.x · DOI
- 10.1210/en.2013-1002 · DOI
- 10.1093/cvr/cvm049 · DOI · Paper page
- 10.1186/s12933-016-0408-3 · DOI · Paper page
- 10.1016/j.jss.2014.07.012 · DOI
- 10.1291/hypres.26.107 · DOI
- 10.3389/fphar.2020.00635 · DOI
- 10.1016/j.ejphar.2020.173458 · DOI
- 10.1016/j.avsg.2018.05.054 · DOI
- 10.1074/mcp.M113.027649 · DOI
- 10.1186/s12933-017-0501-2 · DOI
- 10.1016/j.bbrc.2017.03.036 · DOI
- 10.3390/molecules23051184 · DOI · Paper page
- 10.2147/DDDT.S233932 · DOI
- 10.1016/j.freeradbiomed.2019.05.031 · DOI
- 10.1161/ATVBAHA.113.301938 · DOI · Paper page
- 10.1038/sj.cdd.4401373 · DOI · Paper page
- 10.2337/db15-1657 · DOI
- 10.1038/s41440-019-0212-z · DOI
- 10.1016/j.intimp.2016.10.002 · DOI
- 10.1161/CIRCRESAHA.110.226928 · DOI · Paper page
- 10.1242/bio.043653 · DOI
- 10.1002/dmrr.3173 · DOI
- 10.1007/s10557-018-6773-2 · DOI
- 10.1152/ajprenal.00495.2014 · DOI
- 10.3389/fcell.2021.603802 · DOI
- 10.1155/2013/463740 · DOI
- 10.1016/j.bbadis.2013.05.023 · DOI
- 10.1038/s41598-017-10612-7 · DOI
- 10.1111/acel.12904 · DOI
- 10.1016/j.bbadis.2017.10.014 · DOI
- 10.1371/journal.pone.0207947 · DOI
- 10.1177/2042018820926000 · DOI
- 10.1089/chi.2019.0040 · DOI
- 10.1111/j.1365-2125.2010.03783.x · DOI
- 10.1007/s40263-018-0571-z · DOI
- 10.2337/diacare.2951083 · DOI · Paper page
- 10.1542/peds.2016-4285 · DOI
- 10.2337/diabetes.55.03.06.db05-0917 · DOI
- 10.1016/j.gheart.2017.10.003 · DOI
- 10.1097/00003677-200510000-00007 · DOI
- 10.1016/j.nut.2019.01.019 · DOI
- 10.1111/dom.12826 · DOI
- 10.1007/s00125-016-3992-6 · DOI
- 10.1111/dom.13519 · DOI · Paper page
- 10.7150/jca.50376 · DOI
- 10.3390/cancers13010099 · DOI
- 10.1038/s41591-020-0945-x · DOI · Paper page
- 10.1016/j.envpol.2021.116504 · DOI
- 10.1002/dmrr.681 · DOI · Paper page
- 10.1016/j.ajo.2018.08.053 · DOI
- 10.3389/fnagi.2018.00227 · DOI
- 10.1097/WAD.0000000000000202 · DOI · Paper page
- 10.1080/14737175.2021.1847645 · DOI
- 10.1016/j.bbrc.2016.05.148 · DOI
- 10.1155/2020/9741369 · DOI
- 10.1007/s12035-016-9895-1 · DOI
- 10.1007/s11064-018-2525-8 · DOI
- 10.1016/j.neulet.2020.135440 · DOI
- 10.1038/s41598-017-15662-5 · DOI
- 10.1016/j.phrs.2018.10.027 · DOI
- 10.3892/mmr.2018.8541 · DOI
- 10.1016/j.ejphar.2015.06.010 · DOI
- 10.1016/j.ynpai.2020.100048 · DOI
- 10.1016/j.intimp.2019.05.057 · DOI
- 10.1016/j.ynpai.2020.100048 · DOI
- 10.2147/JPR.S52205 · DOI
- 10.1016/j.bbrc.2020.06.146 · DOI
- 10.1007/s11064-018-2642-4 · DOI
- 10.1016/j.ejphar.2019.172497 · DOI
- 10.1515/med-2019-0071 · doi:10.1515/med-2019-0071
- 10.1096/fj.14-267146 · DOI · Paper page
- 10.1007/s00210-020-01989-w · DOI
- 10.1152/jn.00417.2020 · DOI
- 10.1213/ANE.0000000000004057 · DOI
- 10.1007/s10753-020-01388-6 · DOI
- 10.1002/ejp.1747 · DOI
- 10.1007/s00384-018-3104-9 · DOI
- 10.1111/1753-0407.12900 · DOI · Paper page
- 10.1007/s11739-014-1157-5 · DOI
- Khyalappa R. J., 2020, Group 100, 31.25
- 10.1038/s41598-021-81631-8 · DOI
- Sidle, J. Optimizing Peripheral Neuropathy Management Through Vitamin B12 Screening in Adults With Type Two Diabetes Mellitus Taking Metformin. Doctor of Nursing Practice (DNP) thesis, 2020; https://athenaeum.uiw.edu/uiw_dnp/80 (accessed 2021-10-28).
- 10.1136/bmjdrc-2019-001151 · DOI
- Friberg E., 2007, Diabetes mellitus and risk of endometrial cancer: a meta-analysis
- 10.1038/sj.bjc.6602619 · DOI · Paper page
- 10.1016/j.ejca.2013.02.025 · DOI
- 10.1002/ijc.26165 · DOI · Paper page
- 10.1210/jc.2012-1267 · DOI · Paper page
- 10.3389/fendo.2019.00617 · DOI · Paper page
- 10.1007/s00384-020-03676-x · DOI
- 10.1530/EJE-20-0795 · DOI
- 10.1111/jcpt.13167 · DOI
- 10.1016/j.aohep.2019.11.008 · DOI
- 10.1016/j.aohep.2019.10.005 · DOI
- 10.1038/s41598-018-38285-w · DOI
- 10.1016/j.ygyno.2017.07.120 · DOI
- 10.2147/CMAR.S200059 · DOI · Paper page
- 10.3892/ol.2017.7412 · DOI
- 10.3892/mmr.2016.6094 · DOI
- 10.21037/tlcr-20-1072 · DOI
- 10.21037/atm.2019.06.40 · DOI
- 10.1016/S1471-4892(03)00071-7 · DOI · Paper page
- 10.3389/fonc.2014.00064 · DOI · Paper page
- 10.1016/j.gene.2020.144892 · DOI
- 10.1186/s12943-017-0700-1 · DOI · Paper page
- 10.1007/s11010-015-2651-4 · DOI
- 10.1038/onc.2012.563 · doi:10.1038/onc.2012.563
- 10.1371/journal.pone.0178865 · DOI
- 10.1186/s13046-019-1061-y · DOI
- 10.1016/j.celrep.2018.02.049 · DOI · Paper page
- 10.26355/eurrev_201911_19554 · doi:10.26355/eurrev_201911_19554
- 10.18632/oncotarget.3327 · DOI
- 10.1016/j.ygyno.2009.09.024 · DOI · Paper page
- 10.1080/15384101.2016.1151581 · DOI · Paper page
- 10.1186/1756-9966-28-152 · DOI
- 10.1128/MCB.05437-11 · DOI
- 10.3389/fonc.2019.01399 · DOI · Paper page
- 10.1158/1078-0432.CCR-18-0420 · DOI · Paper page
- 10.1016/j.oraloncology.2018.08.015 · DOI
- 10.1158/1535-7163.MCT-17-0927 · DOI
- 10.1016/j.canlet.2016.12.031 · DOI
- 10.3390/ijms19113692 · DOI
- 10.3390/cells9010217 · DOI · Paper page
- 10.1080/15384047.2018.1529108 · DOI
- 10.1016/j.jhep.2018.11.034 · DOI · Paper page
- 10.1016/j.pharep.2017.11.007 · DOI
- 10.1084/jem.20181739 · DOI · Paper page
- 10.3892/ol.2020.12292 · DOI
- 10.3892/or.2018.6751 · DOI
- 10.1038/ncomms1859 · DOI · Paper page
- 10.1111/cas.13591 · DOI
- 10.1038/35000025 · DOI · Paper page
- 10.18632/oncotarget.23317 · DOI
- 10.1016/j.biocel.2018.12.016 · DOI
- 10.3390/ijms20010229 · DOI
- 10.1111/cas.14124 · DOI
- 10.18632/aging.103777 · DOI
- 10.1016/j.biopha.2017.07.035 · DOI
- 10.1016/j.gde.2008.01.016 · DOI · Paper page
- 10.1371/journal.pone.0143596 · DOI
- 10.1007/s10495-015-1158-5 · DOI
- 10.1007/s10529-013-1309-0 · DOI
- 10.1200/JCO.2005.03.7689 · DOI · Paper page
- 10.2174/156800908784293659 · DOI · Paper page
- 10.1016/j.bbrc.2012.07.165 · DOI · Paper page
- 10.7314/APJCP.2015.16.1.221 · DOI
- 10.3390/ijms17081298 · DOI
- 10.1038/s41389-020-00290-y · DOI
- 10.1038/nrc2347 · DOI · Paper page
- 10.1016/j.bbcan.2011.03.002 · DOI
- 10.1002/jcp.27269 · DOI
- 10.1016/j.ebiom.2017.10.009 · DOI
200 of 313 shown
Cited by
Novel Role of the SIRT1 in Endocrine and Metabolic Diseases
Lu, C., Zhao, H., Liu, Y., Yang, Z., Yao, H., Liu, T., Gou, T., Wang, L., Zhang, J., Tian, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78654 · Cited by 160
“Clinical trials and observational studies have found that metformin can prevent or mitigate PCOS through SIRT1-related pathways [125].”
Tkaczenko, H., & Kurhaluk, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031098 · Cited by 80
“The interactions between Nrf2 and other signalling pathways, including AMPK, NF-κ B, and PI3K/Akt, underscore the complexity of molecular mechanisms governing metabolic health, as highlighted in numerous studies [155,234].”
InfluentialMuhammed Saeed, A. A., Noreen, S., Awlqadr, F. H., Farooq, M. I., Qadeer, M., Rai, N., Farag, H. A., & Saeed, M. N. (2025) · Journal of Health, Population and Nutrition · doi:10.1186/s41043-025-00899-y · Cited by 29
Dhiman, S., Mannan, A., Taneja, A., Mohan, M., & Singh, T. G. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122537 · Cited by 25
Metadata
- Authors
- Ala, M., & Ala, M.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-11-01
- Volume
- 4
- Issue
- 6
- Pages
- 1747-1770
- ISSN
- 2575-9108 (ISSN-L)
- OpenAlex
- W3208206186
- Cited by
- 95
- References
- 70
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next? https://app.cochat.ai/papers/10.1021/acsptsci.1c00167
- The paper
- Ala, M., & Ala, M. (2021). Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next? ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.1c00167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.